Solutions

Online Inquiry

* Your Name

* Phone Number

* E-mail Address

* Services Interested

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Ciliary Body Melanoma

Ciliary body melanoma is an unusual type of ocular melanoma that arises from the ciliary body, which is responsible for the secretion of aqueous humor and regulating the accommodation of the eye lens. Leveraging advanced technologies and a deep understanding of ocular tumors, Protheragen provides tailored solutions to accelerate the development of diagnostics and therapeutics for ciliary body melanoma.

Overview of Ciliary Body Melanoma

Ciliary body melanoma originates from the melanocytes of a part of the uveal tract, which is called the ciliary body. The latter makes ciliary body melanoma an extremely rare yet aggressive intraocular melanoma form. The malignancy has a high risk of metastasis, the most common-looking sites being the liver, lung, skin, and bones. Because it is located behind iris diaphragm, this type of melanoma is extremely difficult to be diagnosed which greatly contributes to it being one of the most aggressive cancers. Moreover, early detection is crucial for greater intervention so as to prevent rapid progression which causes huge mortality and morbidity.

The immunohistochemical stain was strongly positive for HMB-45.

Fig.1 A case analysis of immunohistochemical staining of large ciliary body melanoma. (Tigari B., et al., 2021)

Diagnostics Development for Ciliary Body Melanoma

Molecular diagnostics is critical in diagnosing and forecasting ciliary body melanoma through the analysis of mutations in GNAQ and GNA11. These mutations are markers for determining the most appropriate therapeutics and for selecting cases that will have maximal benefit from the therapy. Next-generation sequencing (NGS) platforms allow broad-scope analysis of tumor samples for revealed genetic changes that are responsible for tumor development and spread.

Therapeutics Development for Ciliary Body Melanoma

Immunotherapy

Targeted therapies aim to inhibit specific molecular pathways involved in tumor growth. Examples include:

MEK Inhibitors: Target the MAPK/ERK pathway, which is frequently activated in ciliary body melanoma.
HDAC Inhibitors: Modulate epigenetic changes, potentially restoring normal gene expression.

Targeted Therapy

Immunotherapy harnesses the immune system to combat cancer. Examples include:

Immune Checkpoint Inhibitors: Drugs such as pembrolizumab and nivolumab block PD-1/PD-L1 interactions, enhancing anti-tumor immunity.
Adoptive Cell Therapy: Involves the infusion of genetically modified T cells to target tumor-specific antigens.

Our Services

Protheragen provides all-encompassing services for the development of diagnostics and therapeutics for ciliary body melanoma. Our expertise spans molecular diagnostics, preclinical research, and customized therapeutic development.

Diagnostics Development

Karyotype Analysis Service
Omics Analysis Service
Biomarker Development Service
Artificial Intelligence Service

Therapeutic Development

Small Molecule Drug
Cell Therapy
Gene Therapy
Therapeutic Antibody
Therapeutic Peptide
Therapeutic Protein
Customized Therapy Development

Disease Models

Syrian Hamster Spontaneous Tumor Models
Murine Models with Human Cells
Human Tumor Cell Induction Zebrafish Models
Chick Embryo Models

Preclinical Research

Pharmacodynamics Study Services
Pharmacokinetics Study Services
Drug Safety Evaluation Services
Customized Research Services

In the pursuit of novel innovations, Protheragen focuses on the research and development of ciliary body melanoma therapy. We combine scientific expertise with an innovative spirit. We take this integrated approach to guarantee that our clients are provided with the highest quality services which are aimed at relocating their projects from the concept stage to clinical practice. If you are interested in our services, please feel free to contact us.

Reference

Tigari, Basavaraj, et al. "Large ciliary body melanoma." BMJ Case Reports 14.11 (2021).